<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577746</url>
  </required_header>
  <id_info>
    <org_study_id>0306-37</org_study_id>
    <secondary_id>IRB # 0306-37</secondary_id>
    <nct_id>NCT00577746</nct_id>
  </id_info>
  <brief_title>Clinical Impact of EUS in Staging NSCLC</brief_title>
  <official_title>The Clinical Impact of Endoscopic Ultrasound (EUS) in Staging Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richard L. Roudebush VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective study is to determine the clinical and economic impact of&#xD;
      endoscopic ultrasound (EUS) in staging NSCLC. Aims: 1) Determine the accuracy of EUS in&#xD;
      staging NSCLC 2) Measure 5-year survival 3) Measure quality of life in patients that undergo&#xD;
      surgery 4) Determine the cost benefit of EUS in staging NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the accuracy of EUS in staging NSCLC</measure>
    <time_frame>at the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure 5-year survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the cost benefit of EUS in staging NSCLC</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure quality of life in patients that undergo surgery</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Non Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <description>Those subjects who went to surgery for treatment for their lung cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no surgery</arm_group_label>
    <description>The subjects who did not go to surgery for treatment of their lung cancer.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Potentially resectable lung cancer subjects see at thoracic oncology clinics and&#xD;
        gastroenterolgy lab.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any subject with presumed or known potentially resectable NSCLC&#xD;
&#xD;
          -  Due to the nature of NSCLC, children (&lt;18 year of age) will not be considered&#xD;
&#xD;
          -  Men, women, and minorities&#xD;
&#xD;
          -  Subjects must be able to safely undergo conscious sedation for the EUS procedure&#xD;
&#xD;
          -  Subjects must be surgical candidates&#xD;
&#xD;
          -  Subjects must not have an uncorrectable coagulopathy and must be able to refrain from&#xD;
             the used of aspirin one week prior to the EUS&#xD;
&#xD;
          -  Patient must provide signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of previously treated lung, head &amp; neck, or esophageal cancer&#xD;
             are not eligible if the histologic cell type is determined to be the same as what is&#xD;
             biopsied during the EUS-FNA&#xD;
&#xD;
          -  Uncorrectable coagulopathy&#xD;
&#xD;
          -  Significant co-morbidities such as uncontrolled heart failure, or severe chronic&#xD;
             obstructive pulmonary disease (COPD) that would limit their survivability to surgery&#xD;
&#xD;
          -  Evidence of significant active infection (e.g. pneumonia, peritonitis, wound abscess)&#xD;
&#xD;
          -  Evidence of serious ongoing illness such as uncontrolled metabolic disease (diabetes&#xD;
             mellitus, hypothyroidism, etc.) or cardiac condition&#xD;
&#xD;
          -  Evidence of dementia or altered mental status that would prohibit the giving and&#xD;
             understanding of informed consent, and no evidence of psychiatric illness that would&#xD;
             preclude adequate compliance with this protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia LeBlanc, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Medical Center; Clarian Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Small Cell Lung</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

